Pre-made Bintrafusp benchmark antibody ( Whole mAb Fusion, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bintrafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Bintrafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody |
|---|---|
| INN Name | Bintrafusp |
| Target | CD274 |
| Format | Whole mAb Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 4nki:HL/5grj:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | AIO Studien gGmbH,Array BioPharma,Chong Kun Dang,Dana-Farber Cancer Institute,Debiopharm,eFFECTOR Therapeutics,EMD Serono,Forty Seven,Fred Hutchinson Cancer Research Center,Gachon University Gil Medi |
| Conditions Approved | Merkel cell carcinoma,Urogenital cancer |
| Conditions Active | Renal cell carcinoma,Breast cancer,Diffuse large B cell lymphoma,Gastric cancer,Head and neck cancer,Non-small cell lung cancer,Ovarian cancer,Bladder cancer,Endometrial cancer,Fallopian tube cancer, |
| Conditions Discontinued | NA |
| Development Tech | Human Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | CD274/PD-L1 |
| Package |
